(51 days)
P970007
Not Found
No
The description focuses on the chemical assay and sample preparation process, with no mention of AI or ML technologies. The performance studies are standard method comparisons.
No.
The device is an in vitro diagnostic assay used to measure tacrolimus levels in blood to aid in managing therapy, not to directly treat patients.
Yes
The "Intended Use" and "Device Description" sections explicitly state that "The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy" and "is for in vitro diagnostic use".
No
The device is described as an in vitro diagnostic assay comprised of antibody, buffer, and enzyme reagents, and an accessory reagent for sample pretreatment. These are physical components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The description explicitly states "for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood". The term "in vitro" means "in glass" or "outside the body," which is a key characteristic of IVDs. It also states it's "as an aid in the management of tacrolimus therapy," indicating a diagnostic purpose.
- Device Description: The description reiterates "for in vitro diagnostic use" and describes the assay components and how they interact with a biological sample (human whole blood) to measure a substance (tacrolimus and metabolite).
- Sample Type: The device analyzes human whole blood, a biological sample.
- Purpose: The purpose is to provide quantitative analysis of a substance in a biological sample to aid in patient management.
All of these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients.
The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay.
Product codes
MLM
Device Description
The Emit® 2000 Tacrolimus Assay is for in vitro diagnostic use for the quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Assay is comprised of an antibody reagent, a buffer reagent and an enzyme reagent. This assay contains mouse monoclonal antibodies with a high specificity for tacrolimus.
The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is used to pretreat the whole blood samples, calibrators, and controls prior to testing with the Emit® 2000 Tacrolimus Assay. The pretreatment process lyses the cells, extracts the tacrolimus, and precipitates most of the blood proteins. The pretreated samples are centrifuged, and an aliquot of the resulting supernatant containing tacrolimus is then assayed using the Emit® 2000 Tacrolimus Assay.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human whole blood
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Method comparison studies were conducted at two external sites comparing the Emit® 2000 Tacrolimus Assay against two predicates: liquid chromatography / mass spectrometry (LC/MS) and Abbott IMx® Tacrolimus II Assay. Samples from 2 transplant groups (liver and kidney) were included in the studies. The data from both sites were pooled and analyzed by linear regression.
Comparative Method: LC/MS/MS
All samples: Slope 1.15, Intercept -0.33, r 0.940, n 197
Kidney: Slope 1.10, Intercept -0.12, r 0.899, n 90
Liver: Slope 1.01, Intercept 0.35, r 0.946, n 65
Comparative Method: Abbott IMx® Tacrolimus II Assay
All samples: Slope 0.92, Intercept -0.04, r 0.881, n 192
Kidney: Slope 0.79, Intercept 0.87, r 0.863, n 88
Liver: Slope 0.83, Intercept 0.69, r 0.812, n 62
Key Metrics
Not Found
Predicate Device(s)
P970007
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1678 Tacrolimus test system.
(a)
Identification. A tacrolimus test system is a device intended to quantitatively determine tacrolimus concentrations as an aid in the management of transplant patients receiving therapy with this drug. This generic type of device includes immunoassays and chromatographic assays for tacrolimus.(b)
Classification. Class II (special controls). The special control is “Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA.” See § 862.1(d) for the availability of this guidance document.
0
Dade Behring Inc. 510(k) Premarket Notification e-submission 510(x) Premail.co. Homes Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent
510(k) Summary Emit® 2000 Tacrolimus Assay Emit® 2000 Tacrolimus Sample Pretreatment Reagent
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
The assigned 510(k) number is:
Manufacturer's Name, Address, Telephone, and Contact Person, Date of 1. Preparation
Manufacturer:
Dade Behring Inc. 20400 Mariani Ave. Cupertino, CA 95014
Contact Information:
Dade Behring Inc. P.O. Box 6101 Newark, DE 19714 Attn: Yuk-Ting Lewis Tel: 302-631-7626
Date of Preparation:
February 7, 2006
Device Name / Classification 2.
Emit® 2000 Tacrolimus Assay / Class II Emit@ 2000 Tacrolimus Sample Pretreatment Reagent / Class II
3. Identification of the Predicate Device
Abbott IMx® Tacrolimus II Assay and Pretreatment Reagent, P970007 (Note: Tacrolimus test systems have been reclassified into Class II since the predicate was approved.)
1
Dade Behring Inc. 510/k) Premarket Notification e-submission Emit® 2000 Tacrolimus Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent
4. Device Description
The Emit® 2000 Tacrolimus Assay is for in vitro diagnostic use for the quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Assay is comprised of an antibody reagent, a buffer reagent and an enzyme reagent. This assay contains mouse monoclonal antibodies with a high specificity for tacrolimus.
The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is used to pretreat the whole blood samples, calibrators, and controls prior to testing with the Emit® 2000 Tacrolimus Assay. The pretreatment process lyses the cells, extracts the tacrolimus, and precipitates most of the blood proteins. The pretreated samples are centrifuged, and an aliquot of the resulting supernatant containing tacrolimus is then assayed using the Emit® 2000 Tacrolimus Assay.
5. Device Intended Use
The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients.
The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay.
Medical device to which equivalence is claimed and comparison information 6.
The Emit® 2000 Tacrolimus Assay and EMIT® 2000 Pretreatment Reagent are substantially equivalent in intended use and technological characteristics to the Abbott IMx® Tacrolimus II Assay and Pretreatment Reagent. Both devices are immunoassays intended for use in the quantitative measurement of tacrolimus in human whole blood. Both devices require a manual pretreatment. The Emit® 2000 Tacrolimus Assay has an assay range of 2-30 ng/mL. The Abbott IMx Tacrolimus II Assay has an assay range of 1.5-30 ng/mL.
2
Dade Behring Inc. 510(k) Premarket Notification e-submission Emit® 2000 Tacrolimus Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent
Comparison Information
Method comparison studies were conducted at two external sites comparing the Emit® 2000 Tacrolimus Assay against two predicates:
- liquid chromatography / mass spectrometry (LC/MS) and .
- . Abbott IMx® Tacrolimus II Assay.
Samples from 2 transplant groups (liver and kidney) were included in the studies. The data from both sites were pooled and analyzed by linear regression.
| Comparative Method | ||||
|---|---|---|---|---|
| LC/MS/MS | Slope | Intercept | r | n |
| All samples | 1.15 | -0.33 | 0.940 | 197 |
| Kidney | 1.10 | -0.12 | 0.899 | 90 |
| Liver | 1.01 | 0.35 | 0.946 | 65 |
| Abbott IMx® Tacrolimus II Assay | ||||
| All samples | 0.92 | -0.04 | 0.881 | 192 |
| Kidney | 0.79 | 0.87 | 0.863 | 88 |
| Liver | 0.83 | 0.69 | 0.812 | 62 |
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health and Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES" written around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
6 2006 APR
Ms. Yuk-Ting Lewis Regulatory Affairs & Compliance Manager Dade Behring Inc. P.O. Box 6101, M/S 514 Newark DE 19714-6101
Re: K060385
Trade/Device Name: Emit®2000 Tacrolimus Assay Emit®2000 Tacrolimus Sample Pretreatment Reagent Regulation Number: 21 CFR§ 862.1678 Regulation Name: Tacrolimus test system Regulatory Class: Class II Product Code: MLM Dated: February 10, 2006 Received: February 14, 2006
Dear Ms. Lewis:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
4
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Alberto G
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Indications for Use
k 060388 510(k) Number (if known):
Emit® 2000 Tacrolimus Assay Device Name: Emit® 2000 Tacrolimus Sample Pretreatment Reagent
Indications For Use:
The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients.
The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay.
Prescription Use ਮ (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 801)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
C.J.C.
e of In Vito Diagnostic Device bation and Safety
060385
Page I of I